Thiard News@F4F

@newsen.bsky.social

1 week ago

Akeso Unveils Promising Results for Cadonilimab Combination Therapy at ELCC 2026 Akeso, Inc. presents compelling findings on cadonilimab's combination therapy for advanced NSCLC at ELCC 2026, marking a significant advancement in cancer treatment.

Akeso Unveils Promising Results for Cadonilimab Combination Therapy at ELCC 2026 #Hong_Kong #Akeso #Cadonilimab #NSCLC

Thiard News@F4F

@newsen.bsky.social

2 weeks ago

Ivonescimab Improves Quality of Life in First-Line NSCLC Patients without Chemotherapy The HARMONi-2 study reveals that Ivonescimab significantly enhances health-related quality of life for NSCLC patients without chemotherapy, outperforming Pembrolizumab.

Ivonescimab Improves Quality of Life in First-Line NSCLC Patients without Chemotherapy #China #Hong_Kong #Akeso #Ivonescimab #NSCLC

Thiard News@F4F

@newsen.bsky.social

2 weeks ago

Akeso Reports Transformative Year with Remarkable Sales Growth in 2025 Akeso, Inc. reported its impressive 2025 annual financial results, showcasing notable growth and advancements in oncology and immunotherapy sectors.

Akeso Reports Transformative Year with Remarkable Sales Growth in 2025 #China #Hong_Kong #Akeso #Cadonilimab #Ivonescimab

Thiard News@F4F

@newsen.bsky.social

4 weeks ago

Akeso Launches Innovative Trispecific Antibody AK150 to Tackle Immunotherapy Resistance in Cancer Treatment Akeso, Inc. has unveiled its groundbreaking trispecific antibody, AK150, which has received IND clearance for clinical trials targeting advanced tumors. This innovation aims to enhance immunotherapy effectiveness.

Akeso Launches Innovative Trispecific Antibody AK150 to Tackle Immunotherapy Resistance in Cancer Treatment #China #Hong_Kong #Immunotherapy #Akeso #AK150

40:40 Recruitment - celia@4040recruitment.co.uk

@4040rec.bsky.social

1 month ago

32-34 NEW PHARMA - In therapies PharmaTimes March explores today's life sciences landscape: patient autonomy where access to medicines is expected. Shifting politics, "super employees," ongoing innovation, GLP-1s, difficult-to-treat...

#obesity #diabetes #typeIIdiabetes #oncology #neurology #rarediseases #womenshealth #EliLilly #Akeso #SummitTherapeutics #precisionmedicine #immunotherapy #Alzheimersdisease #AstraZeneca #DaiichiSankyo #ADCs #precisiononcology #DrugstoWatch2026 #immunology #cardiology #CGTs
zurl.co/c8PJw

Thiard News@F4F

@newsen.bsky.social

1 month ago

Cadonilimab Shows Promising Long-Term Survival Rates in R/M Cervical Cancer Patients Akeso, Inc. reports remarkable 24-month overall survival rates for cadonilimab-treated cervical cancer patients, reshaping treatment protocols.

Cadonilimab Shows Promising Long-Term Survival Rates in R/M Cervical Cancer Patients #China #Hong_Kong #Cancer_Treatment #Akeso #Cadonilimab

Thiard News@F4F

@newsen.bsky.social

1 month ago

Advancing glioblastoma treatment: Akeso and INOVIO's collaboration on innovative therapies Akeso and INOVIO have teamed up to explore a novel combination therapy for glioblastoma, aiming to improve treatment options and patient outcomes in clinical settings.

Advancing glioblastoma treatment: Akeso and INOVIO's collaboration on innovative therapies #China #Hong_Kong #Glioblastoma #Akeso #INOVIO

Thiard News@F4F

@newsen.bsky.social

1 month ago

Innovative Collaboration in Cancer Treatment: INOVIO and Akeso Join Forces for Glioblastoma Therapy INOVIO Pharmaceuticals and Akeso team up to explore a promising therapy for glioblastoma, combining cutting-edge immunotherapy with advanced treatments to tackle this aggressive brain cancer.

Innovative Collaboration in Cancer Treatment: INOVIO and Akeso Join Forces for Glioblastoma Therapy #United_States #Akeso #Cadonilimab #INOVIO #Plymouth_Meeting

Thiard News@F4F

@newsen.bsky.social

2 months ago

Akeso Announces Approval for Phase II Trials of Innovative Bispecific Antibody Targeting Respiratory and Autoimmune Diseases Akeso, Inc. has received approval for Phase II clinical trials for its bispecific antibody, AK139, which targets respiratory and autoimmune diseases, marking a significant advancement in treatment options.

Akeso Announces Approval for Phase II Trials of Innovative Bispecific Antibody Targeting Respiratory and Autoimmune Diseases #China #Hong_Kong #Akeso #bispecific_antibody #AK139

Thiard News@F4F

@newsen.bsky.social

2 months ago

Akeso's Ivonescimab Earns Fifth Breakthrough Therapy Designation for Advanced Biliary Tract Cancer Treatment Akeso, Inc. has achieved a significant milestone with the fifth Breakthrough Therapy Designation for Ivonescimab, targeting advanced biliary tract cancer. This advancement underlines the drug's promising potential.

Akeso's Ivonescimab Earns Fifth Breakthrough Therapy Designation for Advanced Biliary Tract Cancer Treatment #China #Hong_Kong #Akeso #Ivonescimab #biliary_tract_cancer

Thiard News@F4F

@newsen.bsky.social

2 months ago

Akeso's Ivonescimab Recognized Among Game-Changing Drugs for 2026 Akeso's innovative drug, ivonescimab, has been featured in FirstWord Pharma's list of pivotal medicines likely to shape the future of healthcare by 2026. Discover its potential impact.

Akeso's Ivonescimab Recognized Among Game-Changing Drugs for 2026 #China #Hong_Kong #pharmaceuticals #Akeso #Ivonescimab

Thiard News@F4F

@newsen.bsky.social

2 months ago

Akeso's Gumokimab Receives NMPA Acceptance for AS Treatment Akeso, Inc. announces that its supplemental New Drug Application for gumokimab, an IL-17A inhibitor for ankylosing spondylitis, has been accepted.

Akeso's Gumokimab Receives NMPA Acceptance for AS Treatment #China #Hong_Kong #Akeso #Gumokimab #IL-17A

Thiard News@F4F

@newsen.bsky.social

3 months ago

Ivonescimab's Label Update in China: Positive Outcomes for Lung Cancer Patients Akeso, Inc. announces the approval of a significant label update for ivonescimab's dual benefits in progression-free and overall survival, aiding lung cancer patients.

Ivonescimab's Label Update in China: Positive Outcomes for Lung Cancer Patients #China #Hong_Kong #Akeso #Ivonescimab #HARMONi-A

Thiard News@F4F

@newsen.bsky.social

4 months ago

Akeso's Cadonilimab Receives FDA Approval for Phase III Gastric Cancer Trial Akeso, Inc. announces FDA clearance to start a pivotal global trial evaluating cadonilimab for treatment of gastric cancer, comparing it with nivolumab.

Akeso's Cadonilimab Receives FDA Approval for Phase III Gastric Cancer Trial #Hong_Kong #gastric_cancer #Akeso #Cadonilimab

Thiard News@F4F

@newsen.bsky.social

4 months ago

Akeso Unveils Promising Phase II Efficacy Data for Ivonescimab in TNBC Treatment at ESMO IO 2025 Akeso, Inc. presented exciting Phase II clinical trial results for ivonescimab combined with chemotherapy as a first-line treatment for TNBC at ESMO IO 2025.

Akeso Unveils Promising Phase II Efficacy Data for Ivonescimab in TNBC Treatment at ESMO IO 2025 #Hong_Kong #TNBC #Akeso #Ivonescimab

Thiard News@F4F

@newsen.bsky.social

4 months ago

Promising Phase II Results for Cadonilimab in Neoadjuvant Therapy at ESMO Asia 2025 Cadonilimab shows significant promise as a neoadjuvant therapy in resectable gastric cancer, with impressive response rates presented at ESMO Asia 2025.

Promising Phase II Results for Cadonilimab in Neoadjuvant Therapy at ESMO Asia 2025 #Hong_Kong #ESMO_Asia #Akeso #Cadonilimab

Thiard News@F4F

@newsen.bsky.social

4 months ago

Akeso's Breakthrough Drugs Secure Inclusion in China's NRDL, Enhancing Patient Treatment Options Akeso, Inc. announces the successful inclusion of five innovative drugs in China's National Reimbursement Drug List, improving treatment availability for patients.

Akeso's Breakthrough Drugs Secure Inclusion in China's NRDL, Enhancing Patient Treatment Options #China #Hong_Kong #Akeso #Ivonescimab #Ebronucimab

DengYue Medicine

@dengyuemedicine.bsky.social

4 months ago

La NMPA de China aprueba la Ivonescimab Injection para su comercialización

📩 info@dengyuemed.com
🔗https://dengyuepharma.com

#Ivonescimab #IvonescimabInjection #Yidafang #Akeso #AkesóBiofarmacéutica #NMPA #AprobaciónDeMedicamentos #Oncología #CáncerDePulmón #CPNM

Thiard News@F4F

@newsen.bsky.social

4 months ago

Akeso's Groundbreaking Alzheimer's Treatment Approved for Clinical Trials in China Akeso, Inc. has received approval for clinical trials of AK152, a novel bispecific antibody targeting Aβ in Alzheimer's patients, marking a significant development in therapy.

Akeso's Groundbreaking Alzheimer's Treatment Approved for Clinical Trials in China #China #Hong_Kong #Alzheimer's #Akeso #AK152

Thiard News@F4F

@newsen.bsky.social

5 months ago

Akeso Shares Exciting Preclinical Data on IL-1RAP Antibody AK135 at SITC 2025 Akeso reveals promising preclinical findings regarding its antibody AK135 targeting IL-1RAP at SITC 2025, showcasing improved pain relief and safety profiles.

Akeso Shares Exciting Preclinical Data on IL-1RAP Antibody AK135 at SITC 2025 #Hong_Kong #Akeso #National_Harbor,_Maryland #SITC #AK135

Thiard News@F4F

@newsen.bsky.social

5 months ago

Groundbreaking HARMONi-A Study Shows Ivonescimab's Effectiveness in NSCLC Treatment at SITC 2025 The recent presentation of the HARMONi-A study results highlights ivonescimab's significant potential in treating EGFR-mutated NSCLC, showcasing remarkable OS improvements.

Groundbreaking HARMONi-A Study Shows Ivonescimab's Effectiveness in NSCLC Treatment at SITC 2025 #China #Hong_Kong #Akeso #Ivonescimab #HARMONi-A

Thiard News@F4F

@newsen.bsky.social

5 months ago

Akeso's Ivonescimab Achieves Fourth Breakthrough Therapy Designation for TNBC in China Akeso's innovative bispecific antibody, ivonescimab, has now received its fourth Breakthrough Therapy Designation in China for triple-negative breast cancer treatment.

Akeso's Ivonescimab Achieves Fourth Breakthrough Therapy Designation for TNBC in China #China #Hong_Kong #TNBC #Akeso #Ivonescimab

Thiard News@F4F

@newsen.bsky.social

5 months ago

Revolutionary Dual-Positive Immunotherapy for EGFR+ NSCLC Shows Promise at SITC 2025 Akeso's innovative immunotherapy, Ivonescimab, showcases remarkable findings in EGFR+ NSCLC, bolstering treatment options at SITC 2025.

Revolutionary Dual-Positive Immunotherapy for EGFR+ NSCLC Shows Promise at SITC 2025 #Hong_Kong #Akeso #Ivonescimab #HARMONi-A

Thiard News@F4F

@newsen.bsky.social

5 months ago

Cadonilimab Shows Significant Overall Survival Benefits in Advanced Gastric Cancer Clinical Trial at ESMO 2025 At ESMO 2025, Akeso revealed compelling results from the COMPASSION-15 study highlighting cadonilimab’s efficacy for advanced gastric cancer treatment.

Cadonilimab Shows Significant Overall Survival Benefits in Advanced Gastric Cancer Clinical Trial at ESMO 2025 #Hong_Kong #gastric_cancer #Akeso #Cadonilimab

Thiard News@F4F

@newsen.bsky.social

5 months ago

Innovative Ivonescimab Study Accepted by The Lancet for ESMO 2025 Presentation The results from Akeso's Phase III study on ivonescimab have garnered acceptance in The Lancet, set for presentation at ESMO 2025, showcasing significant advances in NSCLC treatment.

Innovative Ivonescimab Study Accepted by The Lancet for ESMO 2025 Presentation #China #Hong_Kong #oncology #Akeso #Ivonescimab

Thiard News@F4F

@newsen.bsky.social

6 months ago

Akeso's Innovative Approach to Pancreatic Cancer: First Patient Dosed in Phase II Study Akeso Inc. has announced a significant milestone in cancer research with the first patient dosed in a Phase II study for advanced pancreatic cancer using a unique antibody fusion protein.

Akeso's Innovative Approach to Pancreatic Cancer: First Patient Dosed in Phase II Study #Hong_Kong #Cancer_Research #Akeso #AK130

Thiard News@F4F

@newsen.bsky.social

6 months ago

Akeso's Ligufalimab Secures FDA Orphan Drug Designation for AML Treatment Akeso's novel IgG4 monoclonal antibody, ligufalimab, has received FDA Orphan Drug Designation for acute myeloid leukemia, aiming to provide better treatment options.

Akeso's Ligufalimab Secures FDA Orphan Drug Designation for AML Treatment #AML #Akeso #Ligufalimab

Thiard News@F4F

@newsen.bsky.social

7 months ago

Akeso Doses First Patient in Groundbreaking Trial for Liver Cancer Treatment Akeso, Inc. announces its first patient has been dosed in a pivotal global trial for a new liver cancer treatment, marking a key advancement in cancer therapy.

Akeso Doses First Patient in Groundbreaking Trial for Liver Cancer Treatment #None #Akeso #Cadonilimab #HCC

Thiard News@F4F

@newsen.bsky.social

7 months ago

Promising Results of Cadonilimab and Pulocimab in Treating Resistance in Lung Cancer Akeso Inc. presents encouraging clinical study results for cadonilimab and pulocimab in treating IO-resistant non-small cell lung cancer, showcasing new hope for patients.

Promising Results of Cadonilimab and Pulocimab in Treating Resistance in Lung Cancer #Hong_Kong #Akeso #Cadonilimab #Pulocimab

Thiard News@F4F

@newsen.bsky.social

7 months ago

Akeso Completes Patient Enrollment in Phase III Trial for Ivonescimab in Biliary Tract Cancer Akeso has announced the completion of patient enrollment for a Phase III trial evaluating ivonescimab in advanced biliary tract cancer against PD-L1 therapy.

Akeso Completes Patient Enrollment in Phase III Trial for Ivonescimab in Biliary Tract Cancer #China #Hong_Kong #Akeso #Ivonescimab #biliary_tract_cancer